Fig. 3: The prevalence of rates of TMB, MSI-H, and CD274 gene amplification in individual tumor types. | Modern Pathology

Fig. 3: The prevalence of rates of TMB, MSI-H, and CD274 gene amplification in individual tumor types.

From: A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

Fig. 3

a In the overall cohort TMB ≥ 10 mutations/Mb was 21.1% (10273/48,782), and TMB ≥ 20 mutations/Mb was 7.7% (3767/48,782). b Overall, for MSI, 1.9% (925/48,782) were MSI-H, 88.6% (43217/48,782) of cases were MSS, and 9.5% (4640/48,782) were MSI-unknown. c The overall prevalence of CD274 amplification in the pan-tumor cohort is 0.72% (350/48,782).

Back to article page